Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Depreciation and Depletion (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Depreciation and Depletion for 15 consecutive years, with $700000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation and Depletion changed 0.0% to $700000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Sep 2025, up 16.67% year-over-year, with the annual reading at $2.5 million for FY2024, 38.89% up from the prior year.
  • Depreciation and Depletion for Q3 2025 was $700000.0 at Xtant Medical Holdings, down from $800000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $800000.0 in Q2 2025, with the low at $200000.0 in Q4 2022.
  • Average Depreciation and Depletion over 5 years is $468421.1, with a median of $400000.0 recorded in 2021.
  • The sharpest move saw Depreciation and Depletion plummeted 42.86% in 2021, then surged 200.0% in 2023.
  • Over 5 years, Depreciation and Depletion stood at $300000.0 in 2021, then plummeted by 33.33% to $200000.0 in 2022, then soared by 200.0% to $600000.0 in 2023, then grew by 16.67% to $700000.0 in 2024, then changed by 0.0% to $700000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $700000.0, $800000.0, and $600000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.